Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Drops By 44.5%

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 147,543 shares, a decline of 44.5% from the April 15th total of 265,805 shares. Based on an average daily volume of 38,559 shares, the short-interest ratio is currently 3.8 days. Currently, 0.8% of the shares of the company are sold short.

Hedge Funds Weigh In On Estrella Immunopharma

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC boosted its position in shares of Estrella Immunopharma by 1,045.7% in the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after purchasing an additional 111,779 shares during the period. Geode Capital Management LLC boosted its position in shares of Estrella Immunopharma by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after purchasing an additional 8,318 shares during the period. Marshall Wace LLP bought a new position in shares of Estrella Immunopharma in the fourth quarter worth approximately $88,000. XTX Topco Ltd boosted its position in shares of Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares during the period. Finally, State Street Corp boosted its position in shares of Estrella Immunopharma by 93.5% in the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares during the period. 0.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ESLA shares. Weiss Ratings raised shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. D. Boral Capital reissued a “buy” rating and set a $8.00 price objective on shares of Estrella Immunopharma in a report on Monday, February 9th. Finally, Wall Street Zen raised shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Estrella Immunopharma presently has a consensus rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Trading Down 7.9%

ESLA stock traded down $0.10 during midday trading on Friday, reaching $1.11. 27,998 shares of the company’s stock traded hands, compared to its average volume of 36,183. Estrella Immunopharma has a 52-week low of $0.78 and a 52-week high of $3.15. The stock has a market cap of $47.36 million, a P/E ratio of -3.17 and a beta of 0.97. The stock’s 50-day moving average is $1.35 and its 200 day moving average is $1.50.

Estrella Immunopharma (NASDAQ:ESLA) last announced its earnings results on Wednesday, March 18th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.17. As a group, research analysts expect that Estrella Immunopharma will post -0.39 EPS for the current fiscal year.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.